The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
The utility of HTS TCR analyses in the management of patients with T-cell malignancies.
Ilan Lanny Kirsch
Stock Ownership - Adaptive Biotechnologies
Anna Sherwood
Stock Ownership - Adaptive Biotechnologies
David Williamson
Stock Ownership - Adaptive Biotechnologies
Wen-Kai Weng
No relevant relationships to disclose
Rachael Clark
No relevant relationships to disclose
Thomas Seth Kupper
No relevant relationships to disclose
David Wu
No relevant relationships to disclose
Harlan Robins
Stock Ownership - Adaptive Biotechnologies (B)